血管生成在子宫腺肌病相关异常子宫出血和不孕中的作用:系统评价。
Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.
机构信息
Department of Obstetrics and Gynecology, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands.
Angiogenesis Laboratory, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
出版信息
Hum Reprod Update. 2019 Sep 11;25(5):647-671. doi: 10.1093/humupd/dmz024.
BACKGROUND
Adenomyosis commonly occurs with abnormal uterine bleeding (AUB) and is associated with subfertility and a higher miscarriage rate. Recent evidence showed abnormal vascularization in the endometrium in patients with adenomyosis, suggesting a role of angiogenesis in the pathophysiology of AUB and subfertility in adenomyosis and providing a possible treatment target.
OBJECTIVE AND RATIONALE
We hypothesized that the level of abnormal vascularization and expression of angiogenic markers is increased in the ectopic and eutopic endometrium of adenomyosis patients in comparison with the endometrium of control patients. This was investigated through a search of the literature.
SEARCH METHODS
A systematic search was performed in PubMed and Embase until February 2019. Combinations of terms for angiogenesis and adenomyosis were applied as well as AUB, subfertility or anti-angiogenic therapy. The main search was limited to clinical studies carried out on premenopausal women. Original research articles focusing on markers of angiogenesis in the endometrium of patients with adenomyosis were included. Studies in which no comparison was made to control patients or which were not published in a peer-reviewed journal were excluded. A second search was performed to explore the therapeutic potential of targeting angiogenesis in adenomyosis. This search also included preclinical studies.
OUTCOMES
A total of 20 articles out of 1669 hits met our selection criteria. The mean vascular density (MVD) was studied by quantification of CD31, CD34, von Willebrand Factor (vWF) or factor-VIII-antibody-stained microvessels in seven studies. All these studies reported a significantly increased MVD in ectopic endometrium, and out of the six articles that took it into account, four studies reported a significantly increased MVD in eutopic endometrium compared with control endometrium. Five articles showed a significantly higher vascular endothelial growth factor expression in ectopic endometrium and three articles in eutopic endometrium compared with control endometrium. The vascular and pro-angiogenic markers α-smooth muscle actin, endoglin, S100A13, vimentin, matrix metalloproteinases (MMPs), nuclear factor (NF)-kB, tissue factor (TF), DJ-1, phosphorylated mammalian target of rapamycin, activin A, folli- and myostatin, CD41, SLIT, roundabout 1 (ROBO1), cyclooxygenase-2, lysophosphatidic acid (LPA) 1,4-5, phospho signal transducer and activator of transcription 3 (pSTAT3), interleukin (IL)-6, IL-22 and transforming growth factor-β1 were increased in ectopic endometrium, and the markers S100A13, MMP-2 and -9, TF, follistatin, myostatin, ROBO1, LPA1 and 4-5, pSTAT3, IL-6 and IL-22 were increased in eutopic endometrium, compared with control endometrium. The anti-angiogenic markers E-cadherin, eukaryotic translation initiation factor 3 subunit and gene associated with retinoic-interferon-induced mortality 19 were decreased in ectopic endometrium and IL-10 in eutopic endometrium, compared with control endometrium. The staining level of vWF and two pro-angiogenic markers (NF-κB nuclear p65 and TF) correlated with AUB in patients with adenomyosis. We found no studies that investigated the possible relationship between markers of angiogenesis and subfertility in adenomyosis patients. Nine articles reported on direct or indirect targeting of angiogenesis in adenomyosis-either by testing hormonal therapy or herbal compounds in clinical studies or by testing angiogenesis inhibitors in preclinical studies. However, there are no clinical studies on the effectiveness of such therapy for adenomyosis-related AUB or subfertility.
WIDER IMPLICATIONS
The results are in agreement with our hypothesis that increased angiogenesis is present in the endometrium of patients with adenomyosis compared with the endometrium of control patients. It is likely that increased angiogenesis leads to fragile and more permeable vessels resulting in adenomyosis-related AUB and possibly subfertility. While this association has not sufficiently been studied yet, our results encourage future studies to investigate the exact role of angiogenesis in the etiology of adenomyosis and related AUB or subfertility in women with adenomyosis in order to design curative or preventive therapeutic strategies.
背景
子宫腺肌病常伴有异常子宫出血(AUB),并与不孕和流产率升高有关。最近的证据表明,子宫腺肌病患者的子宫内膜存在异常血管生成,提示血管生成在 AUB 和不孕的病理生理机制中起作用,并为治疗提供了可能的靶点。
目的和理由
我们假设与对照组患者相比,子宫腺肌病患者的异位和在位子宫内膜中异常血管化和血管生成标志物的表达水平增加。通过文献检索对此进行了研究。
检索方法
在 PubMed 和 Embase 中进行了系统检索,检索时间截至 2019 年 2 月。应用了血管生成和子宫腺肌病的术语组合,以及 AUB、不孕或抗血管生成治疗。主要搜索仅限于在绝经前妇女中进行的临床研究。纳入了重点关注子宫腺肌病患者子宫内膜中血管生成标志物的原始研究文章。排除了未与对照组进行比较或未在同行评议期刊上发表的研究。进行了第二次搜索,以探讨在子宫腺肌病中靶向血管生成的治疗潜力。该搜索还包括临床前研究。
结果
从 1669 项研究中筛选出 20 篇文章符合我们的选择标准。在 7 项研究中,通过定量检测 CD31、CD34、血管性血友病因子(vWF)或因子 VIII 抗体染色的微血管来研究平均血管密度(MVD)。所有这些研究均报告异位子宫内膜的 MVD 显著增加,在考虑到 6 篇文章的情况下,其中 4 篇报告在位子宫内膜的 MVD 也显著增加。5 篇文章显示异位子宫内膜中血管内皮生长因子表达显著升高,3 篇文章显示在位子宫内膜中血管内皮生长因子表达显著升高。与对照组相比,血管和促血管生成标志物 α-平滑肌肌动蛋白、内皮糖蛋白、S100A13、波形蛋白、基质金属蛋白酶(MMPs)、核因子(NF)-kB、组织因子(TF)、DJ-1、磷酸化哺乳动物雷帕霉素靶蛋白、激活素 A、卵泡抑素和肌肉生长抑制素、CD41、SLIT、ROBO1、环氧化酶-2、溶血磷脂酸(LPA)1、4-5、磷酸化信号转导和转录激活因子 3(pSTAT3)、白细胞介素(IL)-6、IL-22 和转化生长因子-β1 在异位子宫内膜中增加,S100A13、MMP-2 和 -9、TF、卵泡抑素、肌肉生长抑制素、ROBO1、LPA1 和 4-5、pSTAT3、IL-6 和 IL-22 在在位子宫内膜中增加,与对照组相比。与对照组相比,异位子宫内膜中 E-钙黏蛋白、真核起始因子 3 亚基和与视黄醇-干扰素诱导死亡 19 相关的基因表达降低,而在位子宫内膜中白细胞介素-10 表达降低。vWF 和两种促血管生成标志物(NF-κB 核 p65 和 TF)的染色水平与子宫腺肌病患者的 AUB 相关。我们没有发现研究调查血管生成标志物与子宫腺肌病患者不孕之间的可能关系。有 9 篇文章报告了在临床研究中直接或间接靶向血管生成,要么测试激素治疗或草药化合物,要么测试临床前研究中的血管生成抑制剂。然而,目前尚无关于此类治疗对子宫腺肌病相关 AUB 或不孕的有效性的临床研究。
意义
研究结果与我们的假设一致,即与对照组患者相比,子宫腺肌病患者的子宫内膜中存在增加的血管生成。可能是增加的血管生成导致脆弱和更易渗透的血管,导致与子宫腺肌病相关的 AUB,并且可能导致不孕。虽然尚未充分研究这种关联,但我们的研究结果鼓励未来的研究调查血管生成在子宫腺肌病的发病机制中的确切作用,以及在子宫腺肌病患者中与 AUB 或不孕相关的血管生成,以设计治疗或预防的治疗策略。